Is there a future for clinical fluorine-18 radiopharmaceuticals (excluding FDG)?

European Journal of Nuclear Medicine

Volumn 25, Issue 12, 1998, Pages 1612-1616

  Stocklin G L ^a  

^a Nuklearmedizinische Klin P   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORIDE; FLUORINE 18; RADIOPHARMACEUTICAL AGENT; SPIPERONE DERIVATIVE;

ARTICLE; DIAGNOSTIC IMAGING; HUMAN; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY;

FLUORINE RADIOISOTOPES; FORECASTING; HUMANS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0042289663     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. IAEA-TECDOC-1007. Directory of cyclotrons used for radionuclide production in Member States. IAEA March 1998
2. 18F labelled 2-deoxy-2-fluoro-D-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med 1977; 18: 990-996.
3. 18F]fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic fluorination. Appl Radiat Isot 1986; 37: 235-238.
4. 18F]fluoroethyl)flumazenil to central benzodiazepine receptors measured in living baboon by positron emission tomography. Eur J Pharmacol 1992; 218: 109-111.
5. 18F]FLT can be used to image cell proliferation in vivo [abstract]. J Nucl Med 1998; 39 (Suppl): 228P.
6. 18F]fluoro-6-thia-heptadecanoic acid in normal human hearts at rest, during exercise and after dipyridamole injection. J Nucl Med 1994; 35: 51-56.
7. 18F]fluorotyrosine, a new tracer of protein synthesis. J Nucl Med 1989; 30:1367-1372.
8. 18F]fluorotyrosine. J Nucl Med 1991; 32: 1338-1346.
9. 18F alpha-methyltyrosine (FMT) in patients [abstract]. J Nucl Med 1998; 39 (Suppl): 53P.
10. Inoue T, Tomiyoshi K, Higuishi T, et al. Biodistribution studies on L-3-[F-18]fluoro-alpha-methyltyrosine: a potential tumor detecting agent. J Nucl Med 1998; 39: 663-667.
11. 18F]fluoroethyl)L-tyrosine (FET): a new PET tracer for tumour imaging. J Nucl Med 1998; in press.
12. Kuwert T, Bartenstein P, Grünwald F, et al. Klinische Wertigkeit der Positronen-Emissions-Tomographie in der Nuklearmedizin: Positionspapier zu den Ergebnissen einer interdisziplinären Konsensuskonferenz. Der Nervenarzt 1998; in press.
13. 18F]N-Methylspiperone: the radioligand of choice for PET studies of the dopamine receptor in human brain. Life Sci 1985; 36: 1359-1366.
14. 18F]benperidol binding to dopamine receptors. J Nucl Med 1994; 35: 122P.
15. 18F labelled butyrophenone neuroleptics exemplified by the synthesis of n.c.a. [18F]N-methylspiperone. Appl Radiat Isot 1995; 46: 911-916.
16. Kung HF, Kim H-J. Kung M-P. et al. Imaging of dopamine transporters with technetium-99m TRODAT-1. Eur J Nucl Med 1996; 23: 1527-1530.
17. Lundquist C, Halldin C, Ginovart N, et al. Development of a fluorine-18 labelled PET radioligand for the dopamine transporter [abstract]: J Nucl Med 1996; (Suppl): 192P.
18. Chaly Th, Dhawan V, Kazumata K et al. Radiosynthesis of [F-18]N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl)nortropane and the first human study with positron emission tomography. Nucl Med Biol 1996; 23: 999-1004
19. 18F dual-labeled altanserin as a metabolically resistant PET ligand for serotonin-2A(5-HT2A) receptor [abstract]. J Nucl Med 1998; 39 (Suppl): 21P.
20. 18F]diprenorphine for central opioid receptor imaging with PET [abstract]. J Nucl Med 1998; 39 (Suppl): 73P.
21. 18F]fluoro-17β-estradiol uptake in metastastic breast carcinoma. J Nucl Med 1991; 32: 1526-1531.
22. Hostetler ED, Jonson SD, Welch MJ, Katzenellenbogen JA. 2-[F18]Fluoroestradiol: A receptor-based radiopharmaceutical with high binding for SHBG [abstract]. J Nucl Med 1998; 39 (Suppl): 35P.
23. Tjuvarev JG, Stockhammer G, Desai R, et al. Imaging the expression of transfected genes in vivo. Cancer Res 1995; 55: 6126-6132.
24. Wester HJ, Hamacher K, Stöcklin G. A comparative study of n.c.a. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol 1996; 23: 365-372.
25. 7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol 1997; 24: 171-178.
26. 2 fragment in normal dogs. Nucl Med Biol 1994; 21: 911-919.
27. 18F PET with cancer of the prostate, thyroid and lung [abstract]. J Nucl Med 1998; 39 (Suppl): 113P.
28. 18F NaF-PET im Vergleich zur konventionellen Skelettszintigraphie mit Tc-99m-MDP. Fortschr Röntgenstr 1998; 168: 1-6.